SEARCH

SEARCH BY CITATION

References

  • 1
    Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004; 103: 698709.
  • 2
    Marcus SM, Flynn HA, Blow FC, Barry KL. Depressive symptoms among pregnant women screened in obstetrics settings. J Womens Health (Larchmt) 2003; 12: 37380.
  • 3
    Meijer WE, Heerdink ER, Leufkens HG, Herings RM, Egberts AC, Nolen WA. Incidence and determinants of long-term use of antidepressants. Eur J Clin Pharmacol 2004; 60: 5761.
  • 4
    Goldstein DJ, Corbin LA, Sundell KL. Effects of first-trimester fluoxetine exposure on the newborn. Obstet Gynecol 1997; 89 (5 Part 1): 7138.
  • 5
    Hendrick V, Smith LM, Suri R, Hwang S, Haynes D, Altshuler L. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 2003; 188: 8125.
  • 6
    Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M, Ormond K, Matsui D, Stein-Schechman AK, Cook L, Brochu J, Rieder M, Koren G. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998; 279: 60910.
  • 7
    Chun-Fai-Chan B, Koren G, Fayez I, Kalra S, Voyer-Lavigne S, Boshier A, Shakir S, Einarson A. Pregnancy outcome of women exposed to bupropion during pregnancy: a prospective comparative study. Am J Obstet Gynecol 2005; 192: 9326.
  • 8
    Simon GE, Cunningham ML, Davis RL. Outcomes of prenatal antidepressant exposure. Am J Psychiatry 2002; 159: 205561.
  • 9
    Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335: 10105.
  • 10
    Sanz EJ, Las-Cuevas C, Kiuru A, Bate A, Edwards R. Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis. Lancet 2005; 365: 4827.
  • 11
    Chambers CD, Hernandez-Diaz S, Van Marter LJ, Werler MM, Louik C, Jones KL, Mitchel AA. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354: 57987.
  • 12
    GlaxoSmithKline Clinical Trial Register. Epidemiology Study: Preliminary Report on Bupropion in Pregnancy and the Occurrence of Cardiovascular and Major Congenital Malformation. Available at http://ctrgskcouk/Summary/paroxetine/epip083.pdf Last accessed 15 November 2005.
  • 13
    Kallen B, Otterblad Olausson P. Antidepressant drugs during pregnancy and infant congenital heart defect. Reprod Toxicol 2006; 21: 2212.
  • 14
    Wogelius P, Norgaard M, Gislum M, Pedersen L, Munk E, Mortensen PB, Lipworth L, Toft Sorensen H. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006; 17: 7014.
  • 15
    Berard A, Ramos E, Rey E, Blais L, St-Andre M, Oraichi D. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007; 80: 1827.
  • 16
    Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 2007; 356: 268492.
  • 17
    Louik C, Lin AE, Werler MM, Hernandez-Diaz S, Mitchell AA. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 2007; 356: 267583.
  • 18
    WHO Collaborating Centre for Drugs Statistics Methodology. Available at http://www.whoccno/atcddd/ Last accessed 2 December 2004.
  • 19
    Tobi H, Van Den Berg PB, De Jong-van den Berg LTW. The Interaction Database: synergy of science and practice in pharmacy. In Medical Data Analysis, eds. BrauseRW, HanischE. Berlin: Springerverlag, 2000; 20611.
  • 20
    Schirm E, Tobi H, De Jong-van den Berg LT. Identifying parents in pharmacy data: a tool for the continuous monitoring of drug exposure to unborn children. J Clin Epidemiol 2004; 57: 73741.
  • 21
    Tobi H, Van Den Berg PB, De Jong-van den Berg LT. Small proportions: what to report for confidence intervals? Pharmacoepidemiol Drug Saf 2005; 14: 23947.
  • 22
    Wen SW, Yang Q, Garner P, Fraser W, Olatunbosun O, Nimrod C, Walker M. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006; 194: 9616.
  • 23
    Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005; 106: 128996.
  • 24
    Schirm EBP, Gebben H, Sauer P, De Jong-van den Berg L. Drug use of children in the community assessed through pharmacy dispensing data. Br J Clin Pharmacol 2000; 50: 4738.
  • 25
    Ververs T, Kaasenbrood H, Visser G, Schobben F, De Jong-van den Berg Egberts T. Prevalence and patterns of antidepressant drug use during pregnancy. Eur J Clin Pharmacol 2006; 62: 86370.
  • 26
    Reefhuis J, Rasmussen SA, Friedman JM. Selective serotonin-reuptake inhibitors and persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354: 218890.
  • 27
    Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S, Donnenfeld A, McCormack M, Leen-Mitchell M, Woodland C, Gardner A, Hom M, Koren G. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993; 269: 22468.
  • 28
    Mitchell AA. Systematic identification of drugs that cause birth defects – a new opportunity. N Engl J Med 2003; 349: 25569.
  • 29
    Bonari L, Pinto N, Ahn E, Einarson A, Steiner M, Koren G. Perinatal risks of untreated depression during pregnancy. Can J Psychiatry 2004; 49: 72635.
  • 30
    Cohen LS, Altshuler LL, Harlow BL, Nonacs R, Newport DJ, Viguera AC, Suri R, Burt VK, Hendrik V, Reminick AM, Loughead A, Vitonis AF, Stowe ZN. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. JAMA 2006; 295: 499507.
  • 31
    ACOG Committee on Obstetric Practice. ACOG Committee Opinion No. 354: treatment with selective serotonin reuptake inhibitors during pregnancy. Obstet Gynecol 2006; 108: 16013.